Centauri Therapeutics Closes £2.5 Million Fundraising
Summary
\xb7 Second tranche of seed financing secured, sufficient to develop first lead candidate through to proof of principle \xb7 \xa31.2m raised in oversubscribed completion of funding round London and Kent, UK, 20th February 2017: Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases and cancer, announced today that it has secured an additional \xa31.2m in funding to complete the seed round, the first tranche of which was raised in January 2016. The funds raised will be used to take the Companys first Alphamer drug candidate for anti-infective therapies through to preclinical proof of concept, a significant value inflection point in the program development, whilst progressing two other anti-bacterial candidates in parallel. Centauris focus on anti-microbial resistance and immuno-oncology medicines are priority markets for the worldwide healthcare agenda, which are forecast to reach a combined total of \xa3100bn by 2020. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected targets. Centauri Therapeutics assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.